



**Stereochemistry abstracts**

Annalisa Guaragna,\* Mauro De Nisco, Silvana Pedatella  
and Giovanni Palumbo

*Tetrahedron: Asymmetry* 17 (2006) 2839



(*R*)-(-)-Undecane-1,2-diol

Ee 90% (NMR)

[ $\alpha$ ]<sub>D</sub><sup>25</sup> = -6.2 (*c* 2.9, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: (*R*)

Annalisa Guaragna,\* Mauro De Nisco, Silvana Pedatella  
and Giovanni Palumbo

*Tetrahedron: Asymmetry* 17 (2006) 2839



(*R*)-(+)-1,2-Epoxyundecane

Ee 90%



[ $\alpha$ ]<sub>D</sub><sup>25</sup> = -9.7 (neat)

Source of chirality: asymmetric synthesis

Absolute configuration: (*R*)

Annalisa Guaragna,\* Mauro De Nisco, Silvana Pedatella  
and Giovanni Palumbo

*Tetrahedron: Asymmetry* 17 (2006) 2839



(*R*)-(-)-3-Hydroxydodecanenitrile

Ee 88% (NMR)


[ $\alpha$ ]<sub>D</sub><sup>25</sup> = -4.3 (*c* 3, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: (*R*)

Annalisa Guaragna,\* Mauro De Nisco, Silvana Pedatella  
and Giovanni Palumbo

*Tetrahedron: Asymmetry* 17 (2006) 2839




(*R*)-(-)-3-Hydroxydodecanoic acid

Ee >99%

[ $\alpha$ ]<sub>D</sub><sup>25</sup> = -17.8 (*c* 1.25, CHCl<sub>3</sub>)


Source of chirality: asymmetric synthesis

Absolute configuration: (*R*)




$C_{22}H_{25}NO_2$   
(*S*)-2-Hydroxymethyl-1- $\{(S_p)\text{-}[2.2]\text{paracyclophane-4-carbonyl}\}$ pyrrolidine

Ee >98%  
 $[\alpha]_D^{24} = +3.3$  (*c* 0.7, CHCl<sub>3</sub>)  
 Source of chirality: (*S*)-prolinol  
 Absolute configuration: (*S<sub>p</sub>,S*)




$C_{22}H_{25}NO_2$   
(*S*)-2-Hydroxymethyl-1- $\{(R_p)\text{-}[2.2]\text{paracyclophane-4-carbonyl}\}$ pyrrolidine

Ee >98%  
 $[\alpha]_D^{24} = -119$  (*c* 0.8, CHCl<sub>3</sub>)  
 Source of chirality: (*S*)-prolinol  
 Absolute configuration: (*R<sub>p</sub>,S*)




$C_{24}H_{29}NO_2$   
(*S*)-2-(1-Hydroxy-1-methyl)ethyl-1- $\{(S_p)\text{-}[2.2]\text{paracyclophane-4-carbonyl}\}$ pyrrolidine

Ee >98%  
 $[\alpha]_D^{23} = -22.0$  (*c* 1.2, CHCl<sub>3</sub>)  
 Source of chirality: (*S*)-1-methyl-1-(pyrrolidin-4-yl)-ethanol  
 Absolute configuration: (*S<sub>p</sub>,S*)




$C_{24}H_{29}NO_2$   
(*S*)-2-(1-Hydroxy-1-methyl)ethyl-1- $\{(R_p)\text{-}[2.2]\text{paracyclophane-4-carbonyl}\}$ pyrrolidine


Ee >98%  
 $[\alpha]_D^{24} = -145$  (*c* 1.3, CHCl<sub>3</sub>)  
 Source of chirality: (*S*)-1-methyl-1-(pyrrolidin-4-yl)-ethanol  
 Absolute configuration: (*R<sub>p</sub>,S*)

 $C_{34}H_{35}NO_2$ (S)-2-(1,1-Diphenyl-1-hydroxy)methyl-1-{(S<sub>p</sub>)-[2.2]paracyclophane-4-carbonyl}pyrrolidine

Ee &gt;98%

 $[\alpha]_D^{25} = -7.1$  (*c* 1.0, CHCl<sub>3</sub>)Source of chirality: (S)- $\alpha,\alpha$ -diphenyl-2-pyrrolidinemethanolAbsolute configuration: (S<sub>p</sub>,S) $C_{34}H_{35}NO_2$ (S)-2-(1,1-Diphenyl-1-hydroxy)methyl-1-{(R<sub>p</sub>)-[2.2]paracyclophane-4-carbonyl}pyrrolidine


Ee &gt;98%

 $[\alpha]_D^{26} = -70.9$  (*c* 1.4, CHCl<sub>3</sub>)Source of chirality: (S)- $\alpha,\alpha$ -diphenyl-2-pyrrolidinemethanolAbsolute configuration: (R<sub>p</sub>,S) $C_{22}H_{27}NO$ (S)-[1-{(S<sub>p</sub>)-[2.2]Paracyclophan-4-yl}methyl]pyrrolidin-2-ylmethanol

Ee &gt;98%

 $[\alpha]_D^{28} = +27.6$  (*c* 0.6, CHCl<sub>3</sub>)

Source of chirality: (S)-prolinol


Absolute configuration: (S<sub>p</sub>,S) $C_{22}H_{27}NO$ (S)-[1-{(R<sub>p</sub>)-[2.2]Paracyclophan-4-yl}methyl]pyrrolidin-2-ylmethanol

Ee &gt;98%

 $[\alpha]_D^{24} = -93.4$  (*c* 0.5, CHCl<sub>3</sub>)

Source of chirality: (S)-prolinol


Absolute configuration: (R<sub>p</sub>,S)

 $C_{24}H_{31}NO$ (S)-1-Methyl-1-[1-[(S<sub>p</sub>)-[2.2]paracyclophan-4-yl]methyl]pyrrolidin-2-yl]ethanol

Ee &gt;98%

 $[\alpha]_D^{27} = +32.7 (c\ 0.3, \text{CHCl}_3)$ 


Source of chirality: (S)-1-methyl-1-(pyrrolidin-4-yl)-ethanol

Absolute configuration: (S<sub>p</sub>,S) $C_{24}H_{31}NO$ (S)-1-Methyl-1-[1-[(R<sub>p</sub>)-[2.2]paracyclophan-4-yl]methyl]pyrrolidin-2-yl]ethanol


Ee &gt;98%

 $[\alpha]_D^{27} = -85.1 (c\ 0.8, \text{CHCl}_3)$ 

Source of chirality: (S)-1-methyl-1-(pyrrolidin-4-yl)-ethanol


Absolute configuration: (R<sub>p</sub>,S) $C_{34}H_{35}NO_2$ (S)-1-[(S<sub>p</sub>)-[2.2]Paracyclophan-4-yl]methyl-2-pyrrolidin-2-yl]ethanol

Ee &gt;98%

 $[\alpha]_D^{25} = -17.9 (c\ 0.8, \text{CHCl}_3)$ Source of chirality: (S)- $\alpha,\alpha$ -diphenyl-2-pyrrolidine-methanolAbsolute configuration: (S<sub>p</sub>,S) $C_{34}H_{35}NO_2$ (S)-1-[(R<sub>p</sub>)-[2.2]Paracyclophan-4-yl]methyl-2-pyrrolidin-2-yl]ethanol


Ee &gt;98%

 $[\alpha]_D^{25} = -59.8 (c\ 0.4, \text{CHCl}_3)$ Source of chirality: (S)- $\alpha,\alpha$ -diphenyl-2-pyrrolidine-methanolAbsolute configuration: (R<sub>p</sub>,S)




Ee >98%  
 $[\alpha]_D^{23} = +28.8$  (*c* 0.5, CHCl<sub>3</sub>)  
 Source of chirality: (*S*)-prolinol  
 Absolute configuration: (*S<sub>p</sub>*)

C<sub>32</sub>H<sub>31</sub>NO<sub>2</sub>  
 N-(2-Hydroxymethyl-2,2-diphenyl)ethyl-N-methyl-[2.2]paracyclophane-4-carboxamide




Ee >98%  
 $[\alpha]_D^{26} = +24.9$  (*c* 0.5, CHCl<sub>3</sub>)  
 Source of chirality: (*S*)-prolinol  
 Absolute configuration: (*S<sub>p</sub>*)

C<sub>32</sub>H<sub>33</sub>NO  
 2-{N-Methyl-N-(*S<sub>p</sub>*)-[2.2]paracyclophanyl methyl}amino-1,1-diphenylethanol




$[\alpha]_D^{20} = -110.7$  (*c* 1.5, CH<sub>2</sub>Cl<sub>2</sub>)  
 Source of chirality: (1*R*,2*S*)-(−)-norephedrine  
 Absolute configuration: (1*S*,2*R*)

C<sub>14</sub>H<sub>19</sub>NO<sub>2</sub>  
 N-[(1*S*,2*R*)-2-Hydroxy-1-methyl-2-phenylethyl]-4-pentenamide



$[\alpha]_D^{20} = -170$  (*c* 0.1, MeOH)  
 Source of chirality: (1*R*,2*S*)-(−)-norephedrine  
 Absolute configuration: (4*S*,5*R*)

C<sub>14</sub>H<sub>17</sub>NO  
 (4*S*,5*R*)-2-(3-Butenyl)-4-methyl-5-phenyl-4,5-dihydro-1,3-oxazole




$[\alpha]_D^{20} = -42.3$  (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>)

Source of chirality: (1*R*,2*S*)-(−)-norephedrine

Absolute configuration: (1*S*,2*R*,5*R*)

C<sub>14</sub>H<sub>18</sub>BrNO<sub>2</sub>  
(1*S*,2*R*,5*R*)-5-Bromomethyl-1-(2-hydroxy-1-methyl-2-phenylethyl)-2-pyrrolidinone




$[\alpha]_D^{20} = -37.6$  (*c* 1.05, CH<sub>2</sub>Cl<sub>2</sub>)

Source of chirality: (1*R*,2*S*)-(−)-norephedrine

Absolute configuration: (1*S*,2*R*,5*S*)

C<sub>14</sub>H<sub>18</sub>BrNO<sub>2</sub>  
(1*S*,2*R*,5*S*)-5-Bromomethyl-1-(2-hydroxy-1-methyl-2-phenylethyl)-2-pyrrolidinone




$[\alpha]_D^{20} = -74$  (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>)

Source of chirality: (1*R*,2*S*)-(−)-norephedrine

Absolute configuration: (1*S*,2*R*,5*R*)

C<sub>14</sub>H<sub>18</sub>INO<sub>2</sub>  
(1*S*,2*R*,5*R*)-5-Iodomethyl-1-(2-hydroxy-1-methyl-2-phenylethyl)-2-pyrrolidinone




$[\alpha]_D^{20} = -49.1$  (*c* 1.1, CH<sub>2</sub>Cl<sub>2</sub>)

Source of chirality: (1*R*,2*S*)-(−)-norephedrine

Absolute configuration: (1*S*,2*R*,5*S*)

C<sub>14</sub>H<sub>18</sub>INO<sub>2</sub>  
(1*S*,2*R*,5*S*)-5-Iodomethyl-1-(2-hydroxy-1-methyl-2-phenylethyl)-2-pyrrolidinone




C<sub>14</sub>H<sub>17</sub>NO<sub>2</sub>  
(2*R*,3*S*,7*a**S*)-3,7*a*-Dimethyl-2-phenyl-pyrrolo[2,1-*b*]oxazol-5(6*H*)-one

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -25 (c 0.25, MeOH)

Source of chirality: (1*R*,2*S*)-(-)-norephedrine

Absolute configuration: (2*R*,3*S*,7*a**S*)




C<sub>23</sub>H<sub>35</sub>NO<sub>7</sub>  
tert-Butyl-(1*S*,3*S*)-1-(ethoxycarbonyl)-3-(benzyloxy)-3-[(*S*)-2,2-dimethyl-1,3-dioxolan-4-yl]propyl carbamate

[ $\alpha$ ]<sub>D</sub><sup>25</sup> = -27.4 (c 1.5, CHCl<sub>3</sub>)

Source of chirality: L-ascorbic acid

Absolute configuration: (1*S*,3*S*,3*a**S*)




C<sub>23</sub>H<sub>35</sub>NO<sub>7</sub>  
tert-Butyl-(1*R*,3*S*)-1-(ethoxycarbonyl)-3-(benzyloxy)-3-[(*S*)-2,2-dimethyl-1,3-dioxolan-4-yl]propyl carbamate

[ $\alpha$ ]<sub>D</sub><sup>25</sup> = -39.1 (c 1.1, CHCl<sub>3</sub>)

Source of chirality: L-ascorbic acid

Absolute configuration: (1*R*,3*S*,3*a**S*)




C<sub>20</sub>H<sub>31</sub>NO<sub>7</sub>  
tert-Butyl-(1*S*,3*S*,4*S*)-1-(ethoxycarbonyl)-3-(benzyloxy)-4,5-dihydroxy pentyl carbamate

[ $\alpha$ ]<sub>D</sub><sup>25</sup> = -14.6 (c 0.7, CHCl<sub>3</sub>)


Source of chirality: L-ascorbic acid

Absolute configuration: (1*S*,3*S*,4*S*)




$[\alpha]_D^{25} = -8.8$  (*c* 1.9, CHCl<sub>3</sub>)  
Source of chirality: L-ascorbic acid  
Absolute configuration: (1*R*,3*S*,4*S*)

C<sub>20</sub>H<sub>31</sub>NO<sub>7</sub>  
*tert*-Butyl-(1*R*,3*S*,4*S*)-1-(ethoxycarbonyl)-3-(benzyloxy)-4,5-dihydroxy pentyl carbamate




$[\alpha]_D^{25} = -17.6$  (*c* 1.25, CHCl<sub>3</sub>)  
Source of chirality: L-ascorbic acid  
Absolute configuration: (1*S*,3*S*,4*S*)

C<sub>26</sub>H<sub>45</sub>NO<sub>7</sub>Si  
*tert*-Butyl-(1*S*,3*S*,4*S*)-1-(ethoxycarbonyl)-3-(benzyloxy)-4-hydroxy-5-(*tert*-butyl dimethyl silyloxy)-pentyl carbamate




$[\alpha]_D^{25} = -18.2$  (*c* 1.25, CHCl<sub>3</sub>)  
Source of chirality: L-ascorbic acid  
Absolute configuration: (1*R*,3*S*,4*S*)

C<sub>26</sub>H<sub>45</sub>NO<sub>7</sub>Si  
*tert*-Butyl-(1*R*,3*S*,4*S*)-1-(ethoxycarbonyl)-3-(benzyloxy)-4-hydroxy-5-(*tert*-butyl dimethyl silyloxy)-pentyl carbamate



$[\alpha]_D^{25} = +5.4$  (*c* 1.3, CHCl<sub>3</sub>)  
Source of chirality: L-ascorbic acid  
Absolute configuration: (2*S*,4*S*,5*R*)


C<sub>21</sub>H<sub>36</sub>NO<sub>4</sub>Si  
(2*S*,4*S*,5*R*)-Ethyl-4-(benzyloxy)-5-(*tert*-butyl dimethyl silyloxy methyl)pyrrolidine-2-carboxylate




$[\alpha]_D^{25} = +21.6$  (*c* 1.8 CHCl<sub>3</sub>)

Source of chirality: L-ascorbic acid

Absolute configuration: (2*R*,4*S*,5*R*)



(2*R*,4*S*,5*R*)-Ethyl-4-(benzyloxy)-5-(*tert*-butyl dimethyl silyloxy methyl)pyrrolidine-2-carboxylate




$[\alpha]_D^{25} = -8.1$  (*c* 0.9, CHCl<sub>3</sub>)

Source of chirality: L-ascorbic acid

Absolute configuration: (2*S*,4*S*,5*R*)




(2*S*,4*S*,5*R*)-Ethyl-4-hydroxy-5-(*tert*-butyl dimethyl silyloxy methyl)pyrrolidine-2-carboxylate




$[\alpha]_D^{25} = +11.7$  (*c* 0.9, CHCl<sub>3</sub>)

Source of chirality: L-ascorbic acid

Absolute configuration: (2*R*,4*S*,5*R*)



(2*R*,4*S*,5*R*)-Ethyl-4-hydroxy-5-(*tert*-butyl dimethyl silyloxy methyl)pyrrolidine-2-carboxylate




$[\alpha]_D^{25} = +11.6$  (*c* 0.75, 1 M HCl)

Source of chirality: L-ascorbic acid

Absolute configuration: (2*S*,4*S*,5*R*)



(2*S*,4*S*,5*R*)-Bulgecinine hydrochloride




$C_6H_{12}NO_4Cl$   
(*2R,4S,5R*)-Bulgecinine hydrochloride

$[\alpha]_D^{25} = +29.8$  (*c* 0.60, 1 M HCl)

Source of chirality: L-ascorbic acid

Absolute configuration: (*2R,4S,5R*)




$C_{12}H_{14}N_4O_3$   
(*3S,4R*)-1-Cbz-3-Azido-4-hydroxypyrrolidine

Ee = 92% [by chiral HPLC]

$[\alpha]_D^{25} = -9.5$  (*c* 1.01,  $CHCl_3$ )

Source of chirality: enzymatic resolution

Absolute configuration: (*3S,4R*)




$C_{14}H_{16}N_4O_4$   
(*3R,4S*)-1-Cbz-3-Acetyloxy-4-azidopyrrolidine

Ee = 97% [by chiral HPLC]

$[\alpha]_D^{25} = -29.3$  (*c* 1.04,  $CHCl_3$ )

Source of chirality: enzymatic resolution

Absolute configuration: (*3R,4S*)



$C_{13}H_{16}N_4O_3$   
(*3R,4S*)-1-Cbz-3-Azido-4-methoxypyrrolidine

Ee = 97% [by chiral HPLC]


$[\alpha]_D^{25} = -48.4$  (*c* 1,  $CHCl_3$ )

Source of chirality: enzymatic resolution

Absolute configuration: (*3R,4S*)

Ahmed Kamal,\* Ahmad Ali Shaik, Mahendra Sandbhor,  
M. Shaheer Malik and Shaik Azeeza

*Tetrahedron: Asymmetry* 17 (2006) 2876



C<sub>18</sub>H<sub>26</sub>N<sub>2</sub>O<sub>5</sub>  
(3*R*,4*S*)-1-Cbz-3-[(*tert*-Butoxycarbonyl)amino]-4-methoxypyrrolidine

Ee = 97% [by chiral HPLC]


[ $\alpha$ ]<sub>D</sub><sup>25</sup> = -7.3 (*c* 1.07, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: (3*R*,4*S*)

Ahmed Kamal,\* Ahmad Ali Shaik, Mahendra Sandbhor,  
M. Shaheer Malik and Shaik Azeeza

*Tetrahedron: Asymmetry* 17 (2006) 2876



C<sub>19</sub>H<sub>28</sub>N<sub>2</sub>O<sub>5</sub>  
(3*R*,4*S*)-1-Cbz-3-[(*tert*-Butoxycarbonyl)methylamino]-4-methoxypyrrolidine

Ee = 97% [by chiral HPLC]


[ $\alpha$ ]<sub>D</sub><sup>25</sup> = -42.6 (*c* 1.05, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: (3*R*,4*S*)

Ahmed Kamal,\* Ahmad Ali Shaik, Mahendra Sandbhor,  
M. Shaheer Malik and Shaik Azeeza

*Tetrahedron: Asymmetry* 17 (2006) 2876



C<sub>16</sub>H<sub>30</sub>N<sub>2</sub>O<sub>5</sub>  
(3*R*,4*S*)-1-*tert*-Butoxycarbonyl-3-methoxy-4{[*tert*-butoxycarbonyl]methylamino}pyrrolidine

Ee = 97% [by chiral HPLC]


[ $\alpha$ ]<sub>D</sub><sup>25</sup> = -53.2 (*c* 1.05, MeOH)

Source of chirality: enzymatic resolution

Absolute configuration: (3*R*,4*S*)

Ahmed Kamal,\* Ahmad Ali Shaik, Mahendra Sandbhor,  
M. Shaheer Malik and Shaik Azeeza

*Tetrahedron: Asymmetry* 17 (2006) 2876






C<sub>16</sub>H<sub>30</sub>N<sub>2</sub>O<sub>5</sub>  
(3*S*,4*R*)-1-*tert*-Butoxycarbonyl-3-methoxy-4{[*tert*-butoxycarbonyl]methylamino}pyrrolidine

Ee = 92% [by chiral HPLC]

[ $\alpha$ ]<sub>D</sub><sup>25</sup> = +50.9 (*c* 1.01, MeOH)

Source of chirality: enzymatic resolution


Absolute configuration: (3*S*,4*R*)


$[\alpha]_D^{28} = +31.8$  (*c* 3.49, EtOH)
Source of chirality: (1*R*,2*S*)-norephedrineAbsolute configuration: (1*S*,2*S*) $C_9H_{13}NO$ (1*S*,2*S*)-2-Amino-1-phenyl-1-propanol
 $[\alpha]_D^{29} = +21.6$  (*c* 2.3, CHCl<sub>3</sub>)
Source of chirality: (1*R*,2*S*)-norephedrineAbsolute configuration: (1*S*,2*S*) $C_{10}H_{11}NO_2$ (4*S*,5*S*)-4-Methyl-5-phenyl-2-oxazolidinone
 $[\alpha]_D^{28} = -31.4$  (*c* 3.49, EtOH)
Source of chirality: (1*S*,2*R*)-norephedrineAbsolute configuration: (1*R*,2*R*) $C_9H_{13}NO$ (1*R*,2*R*)-2-Amino-1-phenyl-1-propanol

Ee = 94% [by chiral HPLC]

 $[\alpha]_D^{25} = -17.7$  (*c* 1.02, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: (5*R*) $C_9H_{14}O_4S$ (5*R*)-Hydroxymethyl-3,5-dimethyl-4-(methoxymethoxy)-(5*H*)-thiophen-2-one



Ee = 98% [by chiral HPLC]


$[\alpha]_D^{25} = -27.9$  (*c* 1.03, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: (5*S*)



(5*S*)-Methylacetate-3,5-dimethyl-4-(methoxymethoxy)-(5*H*)-thiophen-2-one



Ee = 86%


$[\alpha]_D^{25} = -35.4$  (*c* 1.00, CHCl<sub>3</sub>)

Source of chirality: catalytic asymmetric intramolecular cyclopropanation

Absolute configuration: (1*R*,5*R*)



(1*R*,5*R*)-1-(2-Methylphenylsulfonyl)bicyclo[3.1.0]hexan-2-one



Ee = 77%


$[\alpha]_D^{26} = -35.8$  (*c* 1.50, CHCl<sub>3</sub>)

Source of chirality: catalytic asymmetric intramolecular cyclopropanation

Absolute configuration: (1*R*,5*R*)



(1*R*,5*R*)-1-(3-Methylphenylsulfonyl)bicyclo[3.1.0]hexan-2-one



Ee = 69%


$[\alpha]_D^{28} = -25.2$  (*c* 0.75, CHCl<sub>3</sub>)

Source of chirality: catalytic asymmetric intramolecular cyclopropanation

Absolute configuration: (1*R*,5*R*)




(1*R*,5*R*)-1-(4-Methylphenylsulfonyl)bicyclo[3.1.0]hexan-2-one



Ee = &gt; 99%

 $[\alpha]_D^{26} = -37.2$  (*c* 1.02, CHCl<sub>3</sub>)


Source of chirality: catalytic asymmetric intramolecular cyclopropanation

Absolute configuration: (1*R*,5*R*)C<sub>14</sub>H<sub>16</sub>O<sub>3</sub>S(1*R*,5*R*)-1-(2,3-Dimethylphenylsulfonyl)bicyclo[3.1.0]hexan-2-one

Ee = 82%

 $[\alpha]_D^{28} = -43.0$  (*c* 1.05, CHCl<sub>3</sub>)


Source of chirality: catalytic asymmetric intramolecular cyclopropanation

Absolute configuration: (1*R*,5*R*)C<sub>14</sub>H<sub>16</sub>O<sub>3</sub>S(1*R*,5*R*)-1-(2,5-Dimethylphenylsulfonyl)bicyclo[3.1.0]hexan-2-one

Ee = 91%

 $[\alpha]_D^{28} = -50.0$  (*c* 1.25, CHCl<sub>3</sub>)

Source of chirality: catalytic asymmetric intramolecular cyclopropanation


Absolute configuration: (1*R*,5*R*)C<sub>14</sub>H<sub>16</sub>O<sub>3</sub>S(1*R*,5*R*)-1-(2,6-Dimethylphenylsulfonyl)bicyclo[3.1.0]hexan-2-one

Ee = 72%

 $[\alpha]_D^{28} = -42.3$  (*c* 1.09, CHCl<sub>3</sub>)

Source of chirality: catalytic asymmetric intramolecular cyclopropanation


Absolute configuration: (1*R*,5*R*)C<sub>14</sub>H<sub>16</sub>O<sub>3</sub>S(1*R*,5*R*)-1-(3,4-Dimethylphenylsulfonyl)bicyclo[3.1.0]hexan-2-one



Ee = 62%

 $[\alpha]_D^{28} = -41.0$  (*c* 1.37, CHCl<sub>3</sub>)

Source of chirality: catalytic asymmetric intramolecular cyclopropanation

Absolute configuration: (1*R*,5*R*)(1*R*,5*R*)-1-(3,5-Dimethylphenylsulfonyl)bicyclo[3.1.0]hexan-2-one

Ee = 93%

 $[\alpha]_D^{25} = -33.0$  (*c* 1.15, CHCl<sub>3</sub>)

Source of chirality: catalytic asymmetric intramolecular cyclopropanation

Absolute configuration: (1*R*,2*R*)(1*R*,2*R*)-[2-(2,3-Dimethylbenzenesulfonyl)-3-oxocyclopentyl]acetonitrile


Ee = &gt; 99%

 $[\alpha]_D^{24} = -70.1$  (*c* 1.20, CHCl<sub>3</sub>)

Source of chirality: catalytic asymmetric intramolecular cyclopropanation

Absolute configuration: (*R*)

(R)-(3-Oxocyclopentyl)acetonitrile




Ee = 93%

 $[\alpha]_D^{25} = -17.9$  (*c* 0.72, CHCl<sub>3</sub>)

Source of chirality: catalytic asymmetric intramolecular cyclopropanation

Absolute configuration: (*R*)

(R)-[2-(2,3-Dimethylbenzenesulfonyl)-3-methoxy-2-cyclopentenyl]acetonitrile


 $C_{18}H_{19}NO_3S$ 

(R)-[2-(2,3-Dimethylbenzenesulfonyl)-3-(2-propynyloxy)-2-cyclopentenyl]acetonitrile

Ee = 93%

 $[\alpha]_D^{25} = -11.2$  (*c* 0.94, CHCl<sub>3</sub>)

Source of chirality: catalytic asymmetric intramolecular cyclopropanation


Absolute configuration: (*R*) $C_{11}H_{13}NO_2$ 

(S)-4-Benzyl-3-hydroxybutanenitrile

Ee = 98.0% [by chiral HPLC]

 $[\alpha]_D^{20} = -3.3$  (*c* 3.3, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution


Absolute configuration: (3*S*) $C_{11}H_{12}ClNO_2$ 

(S)-4-(4-Chlorobenzyl)-3-hydroxybutanenitrile

Ee = 96.2% [by chiral HPLC]

 $[\alpha]_D^{20} = -2.6$  (*c* 3.2, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: (3*S*) $C_{11}H_{11}Cl_2NO_2$ 


(S)-4-(2,4-Dichlorobenzyl)-3-hydroxybutanenitrile

Ee = 96.1% [by chiral HPLC]

 $[\alpha]_D^{20} = -0.6$  (*c* 3.7, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: (3*S*)




Ee = 97.0% [by chiral HPLC]

 $[\alpha]_D^{20} = -2.6$  (*c* 3.0, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: (3*S*)

C<sub>12</sub>H<sub>15</sub>NO<sub>2</sub>  
(*S*)-4-(4-Methylbenzyloxy)-3-hydroxybutanenitrile




Ee = 96.3% [by chiral HPLC]

 $[\alpha]_D^{20} = -1.8$  (*c* 3.0, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: 3*S*

(S)-4-(4-Methoxybenzyloxy)-3-hydroxybutanenitrile




Ee = 92.7% [by chiral HPLC]

 $[\alpha]_D^{20} = +3.0$  (*c* 3.0, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: 3*S*

(S)-4-(2,4,6-Trimethylbenzyloxy)-3-hydroxybutanenitrile




Ee = 99.0% [by chiral HPLC]

 $[\alpha]_D^{20} = -1.4$  (*c* 3.0, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: 3*S*

(S)-4-(4-Fluorobenzyl)-3-hydroxybutanenitrile




Ee = 70.0% [by chiral HPLC]

 $[\alpha]_D^{20} = +3.4$  (*c* 3.0, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: 3*R*

(R)-3-Acetyloxy-4-benzyloxy-3-hydroxybutanenitrile




Ee = 85.0% [by chiral HPLC]

 $[\alpha]_D^{20} = +4.0$  (*c* 5.0, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: 3*R*

(R)-3-Acetyloxy-4-(4-chlorobenzyloxy)-3-hydroxybutanenitrile




Ee = 90.1% [by chiral HPLC]

 $[\alpha]_D^{20} = +4.6$  (*c* 4.5, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: 3*R*

(R)-3-Acetyloxy-4-(2,4-dichlorobenzyloxy)-3-hydroxybutanenitrile




Ee = 81.3% [by chiral HPLC]

 $[\alpha]_D^{20} = +4.0$  (*c* 3.0, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: 3*R*

(R)-3-Acetyloxy-4-(4-methylbenzyloxy)-3-hydroxybutanenitrile




Ee = 82.3% [by chiral HPLC]

 $[\alpha]_D^{20} = +4.2$  (*c* 5.0, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: 3*R*

(R)-3-Acetoxy-4-(4-methoxybenzyloxy)-3-hydroxybutanenitrile




Ee = 99.0% [by chiral HPLC]

 $[\alpha]_D^{20} = +8.0$  (*c* 3.0, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: 3*R*

(R)-3-Acetoxy-4-(2,4,6-trimethylbenzyloxy)-3-hydroxybutanenitrile




Ee = 85.0% [by chiral HPLC]

 $[\alpha]_D^{20} = +3.0$  (*c* 3.0, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: 3*R*

(R)-4-Acyloxy-(4-fluorobenzyl)-3-hydroxybutanenitrile



Ee = 98.0% [by chiral HPLC]

 $[\alpha]_D^{20} = -13.6$  (*c* 2.0, CHCl<sub>3</sub>)


Source of chirality: enzymatic resolution

Absolute configuration: 5*S*

tert-Butyl (S)-6-(benzyloxy)-5-hydroxy-3-oxohexanoate


Takashi Yamanoi,\* Ryo Inoue, Sho Matsuda, Kaname Katsuraya  
and Keita Hamasaki

*Tetrahedron: Asymmetry* 17 (2006) 2914



$[\alpha]_D^{23} = +70$  (*c* 2.0, CHCl<sub>3</sub>)


Source of chirality: D-glucopyranose



2,3,4,6-Tetra-O-benzyl-alpha-D-glucopyranosyl 2,3,4,6-tetra-O-benzyl-1-C-methyl-alpha-D-glucopyranoside

Takashi Yamanoi,\* Ryo Inoue, Sho Matsuda, Kaname Katsuraya  
and Keita Hamasaki

*Tetrahedron: Asymmetry* 17 (2006) 2914



$[\alpha]_D^{23} = +59$  (*c* 0.83, CHCl<sub>3</sub>)


Source of chirality: D-glucopyranose and D-manno-pyranose



2,3,4,6-Tetra-O-benzyl-alpha-D-mannopyranosyl 2,3,4,6-tetra-O-benzyl-1-C-methyl-alpha-D-glucopyranoside

Takashi Yamanoi,\* Ryo Inoue, Sho Matsuda, Kaname Katsuraya  
and Keita Hamasaki

*Tetrahedron: Asymmetry* 17 (2006) 2914



$[\alpha]_D^{23} = +74$  (*c* 0.95, CHCl<sub>3</sub>)


Source of chirality: D-glucopyranose and D-galactopyranose



2,3,4,6-Tetra-O-benzyl-alpha-D-galactopyranosyl 2,3,4,6-tetra-O-benzyl-1-C-methyl-alpha-D-glucopyranoside


Takashi Yamanoi,\* Ryo Inoue, Sho Matsuda, Kaname Katsuraya  
and Keita Hamasaki

*Tetrahedron: Asymmetry* 17 (2006) 2914



$[\alpha]_D^{23} = +48$  (*c* 0.70, CHCl<sub>3</sub>)


Source of chirality: D-glucopyranose and D-galactopyranose



2,3,4,6-Tetra-O-benzyl-beta-D-galactopyranosyl 2,3,4,6-tetra-O-benzyl-1-C-methyl-alpha-D-glucopyranoside


Takashi Yamanoi,\* Ryo Inoue, Sho Matsuda, Kaname Katsuraya  
and Keita Hamasaki

*Tetrahedron: Asymmetry* 17 (2006) 2914



$[\alpha]_D^{23} = +57$  (*c* 0.81, CHCl<sub>3</sub>)


Source of chirality: D-glucopyranose and D-manno-pyranose



2,3,4,6-Tetra-O-benzyl-alpha-D-glucopyranosyl 2,3,4,6-tetra-O-benzyl-1-C-methyl-alpha-D-mannopyranoside

Carlo Bonini,\* Lucia Chiummiento, Margherita De Bonis,  
Maria Funicello, Paolo Lupattelli and Rocco Pandolfo

*Tetrahedron: Asymmetry* 17 (2006) 2919



Ee = 98%

$[\alpha]_D^{20} = -8.7$  (*c* 0.91, EtOAc)


Source of chirality: AD-mix  $\beta$



(2S,3S)-2,3-Dihydroxy-3-(4-phenyl-thiophen-2-yl)-propionic acid ethyl ester

Carlo Bonini,\* Lucia Chiummiento, Margherita De Bonis,  
Maria Funicello, Paolo Lupattelli and Rocco Pandolfo

*Tetrahedron: Asymmetry* 17 (2006) 2919



Ee = 98%

$[\alpha]_D^{20} = +6.6$  (*c* 0.5, CHCl<sub>3</sub>)


Source of chirality: AD-mix  $\beta$



(2S,3S)-2,3-Dihydroxy-3-(5-phenyl-thiophen-2-yl)-propionic acid ethyl ester

Carlo Bonini,\* Lucia Chiummiento, Margherita De Bonis,  
Maria Funicello, Paolo Lupattelli and Rocco Pandolfo

*Tetrahedron: Asymmetry* 17 (2006) 2919



Ee = 94%

$[\alpha]_D^{20} = +24.4$  (*c* 1.5, CHCl<sub>3</sub>)


Source of chirality: AD-mix  $\beta$



(2S,3R)-2,3-Dihydroxy-4-thiophen-2-yl-butryic acid ethyl ester

Carlo Bonini,\* Lucia Chiummiento, Margherita De Bonis,  
Maria Funicello, Paolo Lupattelli and Rocco Pandolfo

*Tetrahedron: Asymmetry* 17 (2006) 2919




C<sub>16</sub>H<sub>18</sub>O<sub>4</sub>S  
(2*S*,3*R*)-2,3-Dihydroxy-4-(4-phenyl-thiophen-2-yl)-butyric acid ethyl ester

Ee = 88%  
[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +26.6 (*c* 0.5, CHCl<sub>3</sub>)  
Source of chirality: AD-mix  $\beta$

Carlo Bonini,\* Lucia Chiummiento, Margherita De Bonis,  
Maria Funicello, Paolo Lupattelli and Rocco Pandolfo

*Tetrahedron: Asymmetry* 17 (2006) 2919




C<sub>14</sub>H<sub>16</sub>O<sub>4</sub>S  
(2*S*,3*R*)-4-Benzo[b]thiophen-2-yl-2,3-dihydroxy-butyric acid ethyl ester

Ee = 88%  
[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +36.7 (*c* 1.8, CHCl<sub>3</sub>)  
Source of chirality: AD-mix  $\beta$

Carlo Bonini,\* Lucia Chiummiento, Margherita De Bonis,  
Maria Funicello, Paolo Lupattelli and Rocco Pandolfo

*Tetrahedron: Asymmetry* 17 (2006) 2919




C<sub>14</sub>H<sub>16</sub>O<sub>4</sub>S  
(2*S*,3*R*)-4-Benzo[b]thiophen-3-yl-2,3-dihydroxy-butyric acid ethyl ester

Ee = 82%  
[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +18.8 (*c* 1.05, CHCl<sub>3</sub>)  
Source of chirality: AD-mix  $\beta$


Yingjian (Andy) Xu, Gordon F. Docherty, Gary Woodward and  
Martin Wills\*

*Tetrahedron: Asymmetry* 17 (2006) 2925




C<sub>8</sub>H<sub>10</sub>O  
(*S*)-(-)-1-Phenylethanol

Ee 90%  
[ $\alpha$ ]<sub>D</sub><sup>23</sup> = +48.6 (*c* 0.10 CH<sub>2</sub>Cl<sub>2</sub>)  
Determined by chiral GC analysis




C<sub>9</sub>H<sub>9</sub>F<sub>3</sub>O  
(S)-(-)-1-(3'-Trifluoromethylphenyl)ethanol

Ee 93%  
 $[\alpha]_D^{20} = -24.0$  (*c* 0.24, MeOH)  
Determined by chiral GC analysis




C<sub>9</sub>H<sub>9</sub>F<sub>3</sub>O  
(S)-(-)-1-(4'-Trifluoromethylphenyl)ethanol

Ee 90%  
 $[\alpha]_D^{22} = -22.3$  (*c* 0.62, MeOH)  
Determined by chiral GC analysis




C<sub>9</sub>H<sub>9</sub>BrO  
(S)-(-)-1-(2'-Bromophenyl)ethanol

Ee 97%  
 $[\alpha]_D^{26} = -54.5$  (*c* 0.2, CHCl<sub>3</sub>)  
Determined by chiral GC analysis




C<sub>9</sub>H<sub>9</sub>IO  
(S)-(-)-1-(2'-Iodophenyl)ethanol

Ee 97%  
 $[\alpha]_D^{29} = -41.3$  (*c* 0.20, CHCl<sub>3</sub>)  
Determined by chiral GC analysis




C<sub>8</sub>H<sub>9</sub>FO  
(S)-(-)-1-(4'-Fluorophenyl)ethanol

Ee 93%  
 $[\alpha]_D^{30} = -29.3$  (*c* 0.22, CH<sub>3</sub>OH)  
Determined by chiral GC analysis




C<sub>8</sub>H<sub>9</sub>ClO  
(S)-(-)-1-(4'-Chlorophenyl)ethanol

Ee 90%  
 $[\alpha]_D^{29} = -37.8$  (*c* 0.30, ether)  
Determined by chiral GC analysis



C<sub>8</sub>H<sub>9</sub>ClO  
(S)-(-)-1-(3'-Chlorophenyl)ethanol

Ee 90%  
 $[\alpha]_D^{31} = -24.1$  (*c* 0.56, CHCl<sub>3</sub>)  
Determined by chiral GC analysis




C<sub>8</sub>H<sub>9</sub>ClO  
(S)-(-)-1-(2'-Chlorophenyl)ethanol

Ee 94%  
 $[\alpha]_D^{29} = -32.9$  (*c* 0.22, CHCl<sub>3</sub>)  
Determined by chiral GC analysis

Yingjian (Andy) Xu, Gordon F. Docherty, Gary Woodward and Martin Wills\*

Tetrahedron: Asymmetry 17 (2006) 2925



C<sub>9</sub>H<sub>12</sub>O  
(S)-(-)-1-(2'-Methylphenyl)ethanol


Ee 92%

$[\alpha]_D^{24} = -75.0$  (*c* 0.15, EtOH)

Determined by chiral GC analysis

Yingjian (Andy) Xu, Gordon F. Docherty, Gary Woodward and Martin Wills\*

Tetrahedron: Asymmetry 17 (2006) 2925



C<sub>8</sub>H<sub>12</sub>SO  
(S)-(-)-1-(2,5-Dimethyl-3-thienyl)ethanol


Ee 92%

$[\alpha]_D^{28} = -16.4$  (*c* 0.30, CHCl<sub>3</sub>)

Determined by chiral GC analysis

D. Christopher Braddock,\* Stephen A. Hermitage, Joanna M. Redmond and Andrew J. P. White

Tetrahedron: Asymmetry 17 (2006) 2935



C<sub>21</sub>H<sub>18</sub>N<sub>2</sub>  
(+)-(4R,5R)-4,5-Dihydro-2,4,5-triphenyl-1H-imidazole (*iso*-amarine)

Ee = >98%


$[\alpha]_D = +46.0$  (*c* 2.0, EtOH)

Source of chirality: chiral pool

Absolute configuration: (R,R)

D. Christopher Braddock,\* Stephen A. Hermitage, Joanna M. Redmond and Andrew J. P. White

Tetrahedron: Asymmetry 17 (2006) 2935




C<sub>29</sub>H<sub>26</sub>N<sub>2</sub>O<sub>3</sub>  
(+)-(4R,5R)-4,5-Dihydro-2,4,5-triphenyl-1H-imidazolium (*S*)-mandelate

Ee = >98%

$[\alpha]_D = +128.0$  (*c* 2.3, EtOH)

Source of chirality: chiral pool

Absolute configuration: (R,R,S)




Ee = >98%


$[\alpha]_D = +64.9$  (*c* 1.0, 9:1 CHCl<sub>3</sub>-MeOH)

Source of chirality: chiral pool

Absolute configuration: (S,S)



(+-)(1*S*,2*S*)-*N*-Acetyl-*N'*-benzoyl-1,2-diamino-1,2-diphenylethane




Ee = 100%

$[\alpha]_D = -13.4$  (*c* 1.1, CHCl<sub>3</sub>)

Absolute configuration: (3*R*,5*R*)




(3*R*,5*R*)-5-(tert-Butyldiphenylsilyloxy)-3-methyldihydrofuran-2(3*H*)-one




Ee = 100%

$[\alpha]_D = -14.0$  (*c* 0.9, CHCl<sub>3</sub>)

Absolute configuration: (4*R*,6*R*)



(4*R*,6*R*)-7-(tert-Butyldiphenylsilyloxy)-6-hydroxy-4-methylhept-2*E*-enoic acid ethyl ester




Ee = 100%

$[\alpha]_D = +9.1$  (*c* 1.5, CHCl<sub>3</sub>)



Absolute configuration: (2*R*,3*S*,4*R*,6*R*)




(2*R*,3*S*,4*R*,6*R*)-7-(tert-Butyldiphenylsilyloxy)-2,3,6-trihydroxy-4-methylheptanoic acid ethyl ester




Ee = 100%

 $[\alpha]_D = -2.0$  (*c* 1.7, CHCl<sub>3</sub>)Absolute configuration: (4*R*,5*S*,2'*R*,4'*R*)(4*R*,5*S*)-5-[(2*R*,4*R*)-5-(*tert*-Butyldiphenylsilyloxy)-4-hydroxypent-2-yl]-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid ethyl ester

Ee = 100%

 $[\alpha]_D = +7.1$  (*c* 1.6, CHCl<sub>3</sub>)Absolute configuration: (4*R*,5*S*,2'*R*,4'*R*)(4*R*,5*S*)-5-[(2*R*,4*R*)-5-(*tert*-Butyldiphenylsilyloxy)-4-(triethylsilyloxy)pent-2-yl]-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid ethyl ester

Ee = 100%


 $[\alpha]_D = +13.2$  (*c* 1.1, CHCl<sub>3</sub>)Absolute configuration: (4*R*,5*S*,2'*R*,4'*R*)(4*R*,5*S*)-5-[(2*R*,4*R*)-5-(*tert*-Butyldiphenylsilyloxy)-4-(triethylsilyloxy)pent-2-yl]-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid *N*-methoxy-*N*-methylamide

Ee = 100%

 $[\alpha]_D = +17.7$  (*c* 0.8, CHCl<sub>3</sub>)Absolute configuration: (4*R*,5*S*,2'*R*,4'*R*)1-{5-[(2*R*,4*R*)-5-(*tert*-Butyldiphenylsilyloxy)-4-(triethylsilyloxy)pent-2-yl]-(4*R*,5*S*)-2,2-dimethyl-[1,3]dioxolan-4-yl}-ethanone

Takahiro Katoh, Chie Noguchi, Hiroyuki Kimura, Toshio Fujiwara,  
Shogo Ichihashi, Kiyoharu Nishide, Tetsuya Kajimoto and  
Manabu Node\*

*Tetrahedron: Asymmetry* 17 (2006) 2943




(*R*)-(-)-Bis[(1*S*)-(-)-bornyl] 2,3-pentadienedioate

$[\alpha]_D^{26} = -206.8$  (*c* 0.98, CHCl<sub>3</sub>)

Takahiro Katoh, Chie Noguchi, Hiroyuki Kimura, Toshio Fujiwara,  
Shogo Ichihashi, Kiyoharu Nishide, Tetsuya Kajimoto and  
Manabu Node\*

*Tetrahedron: Asymmetry* 17 (2006) 2943




(*R*)-(-)-Bis[(1*R*)-(-)-isobornyl] 2,3-pentadienedioate

$[\alpha]_D^{25} = -263.8$  (*c* 1.43, CHCl<sub>3</sub>)

Takahiro Katoh, Chie Noguchi, Hiroyuki Kimura, Toshio Fujiwara,  
Shogo Ichihashi, Kiyoharu Nishide, Tetsuya Kajimoto and  
Manabu Node\*

*Tetrahedron: Asymmetry* 17 (2006) 2943




(1*S*,2*R*,3*E*,4*R*)-(+)-[(-)-Bornyl] 3-[2-(-)-bornyloxy-2-oxoethylidene]-7-tert-butoxycarbonyl-7-azabicyclo[2.2.1]hept-5-ene-2-carboxylate

$[\alpha]_D^{31} = +19.3$  (*c* 0.64, CHCl<sub>3</sub>)


Takahiro Katoh, Chie Noguchi, Hiroyuki Kimura, Toshio Fujiwara,  
Shogo Ichihashi, Kiyoharu Nishide, Tetsuya Kajimoto and  
Manabu Node\*

*Tetrahedron: Asymmetry* 17 (2006) 2943



(1*S*,2*R*,3*E*,4*R*)-(-)-[(-)-Isobornyl] 3-[2-(-)-isobornyloxy-2-oxoethylidene]-7-tert-butoxycarbonyl-7-azabicyclo[2.2.1]hept-5-ene-2-carboxylate

$[\alpha]_D^{27} = -16.7$  (*c* 2.46, CHCl<sub>3</sub>)



$[\alpha]_D^{26} = -31.5$  (*c* 0.64, CHCl<sub>3</sub>)

C<sub>30</sub>H<sub>42</sub>O<sub>4</sub>

(1*S*,2*R*,3*E*,4*R*)-(-)-[(1*S*)-(-)-Bornyl] 3-[2(-)-bornyloxy-2-oxoethylidene]bicyclo[2.2.1]hept-5-ene-2-carboxylate